Biomarkers associated with coronavirus disease-19 disease progression in a Mexican hospital
Revista Medica del Hospital General de Mexico
; 84(2):64-70, 2021.
Article
in English
| EMBASE | ID: covidwho-1257507
ABSTRACT
Introduction:
The Coronavirus disease (COVID-19) pandemic is a worldwide challenge. There are few useful tools to predict patient outcomes. Identification of biomarkers able to predict progression of the disease could improve the treatment of these patients.Objective:
The objective of the study was to identify biomarkers of disease progression among patients with severe COVID-19 pneumonia. Materials andmethods:
A retrospective cohort study was conducted among severe COVID-19 pneumonia patients hospitalized in the American British Cowdray Medical Center in Mexico City. Disease progression was defined as use of vasoactive amines, need of non-invasive or invasive mechanical ventilation or death. Studied biomarkers included neutrophil/lymphocyte index, lymphocyte/platelet Ratio, C reactive protein, procalcitonin, D Dimer, lactic dehydrogenase (LDH), ferritin, 25–OH–Vitamin D, and interleukin 6.Results:
We report 46 patients with severe COVID-19 pneumonia. Mean age was 51 years, the majority of whom 30 (65%) male. Median hospitalization was 9 days. 23 (50%) of patients presented disease progression. Ferritin and LDH were strongly associated with disease progression among our cohort. In addition, age was associated with worst prognosis with a relative risk 4.5 (1.2-16.9, p = 0.003).Conclusions:
Age, ferritin, and LDH were associated with disease progression among patients with severe COVID-19 pneumonia.
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Country/Region as subject:
Mexico
Language:
English
Journal:
Revista Medica del Hospital General de Mexico
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS